[Home ] [Archive]   [ فارسی ]  
:: Main :: About :: Current Issue :: Archive :: Search :: Submit :: Contact ::
:: Volume 24, Issue 6 (Iranian South Medical Journal 2021) ::
Iran South Med J 2021, 24(6): 610-625 Back to browse issues page
An Introduction to Boron Neutron Therapy (BNCT): Current Status and Future Outlook
Malehe Omrani 1, Esmaeil Jafari2, Zenab Alipour3, Hajar Zarei4
1- Department of Biotechnology, Persian Gulf Research Studies Center, Persian Gulf University, Bushehr, Iran , m.omrani@pgu.ac.ir
2- The Persian Gulf Nuclear Medicine Research Center, The Persian Gulf Biomedical Sciences Research Institute, Bushehr University of Medical Sciences, Bushehr, Iran
3- Department of Infectious Diseases, School of Medicine, Bushehr University of Medical Sciences, Bushehr, Iran
4- Department of Radiation Biotechnology, School of Nanoscience and Biotechnology, Persian Gulf University
Abstract:   (662 Views)
Boron neutron capture therapy (BNCT) is based on the nuclear reaction, such that B-10 irradiated with low-energy thermal neutrons produces alpha particles with high linear energy transfer and lithium-7. Clinically, BNCT is used primarily for treatment of high-grade glioma or brain metastases from melanoma and, more recently, head, neck and liver cancers. Since reactors have long been used to produce high intensity neutron beams, nuclear reactors have also been used to produce BNCT. Accelerators can also be used to generate quasi-thermal neutrons, but none of them are currently used for BNCT. Boron medications with low molecular weight used in clinic include sodium borocaptate (BSH) and a phenylalanine derivative called boronophenyl alanine (BPA). The main challenge in the development of boron tracers is the selective targeting to reach a sufficient concentration of boron (F 20 Ag / g tumor) so that the tumor receives a sufficient dose of radiation and normal tissues receive minimal radiation. Clinical trials of BNCT are being conducted or have been conducted in various countries. Most patients undergoing BNCT were patients with high-grade brain tumors. The patients underwent surgery for complete or partial removal of the tumor and then received BNCT at various time intervals after surgery. BNCT in combination with other treatments such as surgery, chemotherapy and external beam radiotherapy can also be used as an adjuvant therapy for treatment of other tumors. This concomitant use may lead to improvements in patient survival. According to clinical studies, BNCT is a targeted therapy with promising results and acceptable toxicity. Important issues in this treatment include the need for more selective and effective agents for boron delivery carriers, development of methods for estimating semi-quantitative amounts of boron content in the tumor before treatment, clinical progress of BNCT and the need for randomized clinical trials with known therapeutic efficacy. If these issues are addressed enough, BNCT can develop as a treatment method. Further research is needed to determine the role of BNCT in clinical medicine.
Keywords: BNCT, glioblastoma, Boron agents, Accelerator
Full-Text [PDF 555 kb]   (276 Downloads)    
Type of Study: Review | Subject: General
Received: 2021/04/28 | Accepted: 2021/11/8 | Published: 2022/01/15
1. Gutin PH, Posner JB. Neuro-Oncology: Diagnosis and Management Of Cerebral Gliomas--Past, Present, And Future. Neurosurgery 2000; 47(1): 1-8.
2. Assi H, Candolf M, Baker G, et al. Gene Therapy for Brain Tumors: Basic Developments and Clinical Implementation. Neurosci Lett 2012; 527(2): 71-7.
3. Parney I, Chang S. Current Chemotherapy For Glioblastoma. Glioblastoma Multiforme. Sudbury: Jones & Bartlett Learning, 2005, 161-77.
4. Lacroix M, Abi-Said D, Fourney DR, et al. A Multivariate Analysis Of 416 Patients With Glioblastoma Multiforme: Prognosis, Extent Of Resection, And Survival. J Neurosurg 2001; 95(2): 190-8.
5. Laws Jr ER, Shaffrey ME. The Inherent Invasiveness Of Cerebral Gliomas: Implications For Clinical Management. Int J Dev Neurosci 1999; 17(5-6): 413-20.
6. Halperin EC, Burger PC, Bullard DE. The Fallacy Of The Localized Supratentorial Malignant Glioma. Int J Radiat Oncol Biol Phys 1988; 15(2): 505-9.
7. Chen YW, Lee YY, Lin CF, et al. Salvage Boron Neutron Capture Therapy For Malignant Brain Tumor Patients In Compliance With Emergency And Compassionate Use: Evaluation Of 34 Cases In Taiwan. Biology 2021; 10(4): 334.
8. Parney IF, Hao C, Petruk KC. Glioma Immunology And Immunotherapy. Neurosurgery 2000; 46(4): 778-92.
9. Ware ML, Berger MS, Binder DK. Molecular Biology Of Glioma Tumorigenesis. Histol Histopathol 2003; 18(1): 207-16.
10. Barth RF, Coderre JA, Vicente MGH, et al. Boron Neutron Capture Therapy of Cancer: Current Status and Future Prospects. Clin Cancer Res 2005; 11(11): 3987-4002.
11. Neutron Therapy Information. What Are Neutrons And Why Are They Useful In Cancer Therapy? Neutron Therapy. (Accessed August 14, 2021, at http://www.neutrontherapy.com/ neutron_therapy_information.asp)
12. Dymova MA, Taskaev SY, Richter VA, et al. Boron Neutron Capture Therapy: Current Status And Future Perspectives. Cancer Commun 2020; 40(9): 406-21.
13. Gheisari R, Firoozabadi M, Mohammadi H. Optimization Of The Geometry And Composition Of A Neutron System For Treatment By Boron Neutron Capture Therapy. Iran South Med J 2015; 17(6): 1113-9. (Persian)
14. Nedunchezhian K, Aswath N, Thiruppathy M, et al. Boron Neutron Capture Therapy - A Literature Review. J Clin Diagn Res 2016; 10(12): ZE01-ZE04.
15. Kageji T, Nagahiro S, Mizobuchi Y, et al. Boron Neutron Capture Therapy (BNCT) For NewlyDiagnosed Glioblastoma: Comparison Of Clinical Results Obtained With BNCT And Conventional Treatment. J Med Invest 2014; 61(3-4): 254-63.
16. Wagner FM, Loeper-Kabasakal B, Breitkreutz H. Neutron Medical Treatment Of Tumours — A Survey Of Facilities. J Instrum 2012; 7: C03041.
17. Akan Z. Boron Neutron Capture Therapy for Breast Cancer. Int J Women Health Reproduct Sci (IJWHR) 2015; 3(2): 077.
18. Harling OK, Riley KJ. Fission Reactor Neutron Sources For Neutron Capture Therapy- A Critical Review. J Neurooncol 2003; 62: 7-17.
19. Harling OK, Riley KJ, Newton TH, et al. The Fission Converter-Based Epithermal Neutron Irradiation Facility At The Massachusetts Institute Of Technology Reactor. Nucl Sci Eng 2002; 140(3): 223-40.
20. Joensuu H, Kankaanranta L, Seppälä T, et al. Boron Neutron Capture Therapy Of Brain Tumors: Clinical Trials At The Finnish Facility Using Boronophenylalanine. J Neurooncol 2003; 62(1-2): 123-34.
21. Yamamoto K, Kumada H, Torii Y, et al. Characteristics of Neutron Beams at JRR-4 for BNCT. Proceedings of the ninth international symposium on neutron capture therapy for cancer. 2000 Oct. 2-6, Osaka, Japan. 2000. 243-4.
22. Diaz AZ. Assessment Of The Results From The Phase I/II Boron Neutron Capture Therapy Trials At The Brookhaven National Laboratory From A Clinician’s Point Of View. J Neurooncol 2003; 62(1-2): 101-9.
23. Riley KJ, Binns PJ, Harling OK. Performance Characteristics Of The MIT Fission Converter Based Epithermal Neutron Beam. Phys Med Biol 2003; 48(7): 943-58.
24. Bavarnegin E, Kasesaz Y, Wagner FM. Neutron Beams Implemented At Nuclear Research Reactors For BNCT. J Instrum 2017; 12: P05005.
25. Altieri S, Protti N. A Brief Review On Reactor-Based Neutron Sources For Boron Neutron Capture Therapy. Ther Radiol Oncol 2018; 2: 47.
26. International Atomic Energy Agency. Current Status Of Neutron Capture Therapy. IAEA TECDOC No.1223, 2001, 75-7.
27. Blue TE, Yanch JC. Accelerator-Based Epithermal Neutron Sources For Boron Neutron Capture Therapy Of Brain Tumors. J Neurooncol 2003; 62(1-2): 19-31.
28. Kreiner AJ, Bergueiro J, Cartelli D, et al. Present Status Of Accelerator-Based BNCT. Rep Pract Oncol Radiother 2016; 21(2): 95-101.
29. Allen DA, Beynon TD, Green S, et al. Toward A Final Design For The Birmingham Boron Neutron Capture Therapy Neutron Beam. Med Phys 1999; 26(1): 77-82.
30. Swenson DA. An Rf Focused Interdigital Ion Accelerating Structure. AIP Conf Proc 2003; 680: 1013-6.
31. Hatanaka H. A Revised Boron-Neutron Capture Therapy For Malignant Brain Tumors. II. Interim Clinical Result With The Patients Excluding Previous Treatments.J Neurol 1975; 209(2): 81-94.
32. Nakagawa Y, Hatanaka H. Boron Neutron Capture Therapy: Clinical Brain Tumor Studies. J Neurooncol 1997; 33(1-2): 105-15.
33. Nakagawa Y, Pooh K, Kobayashi T, et al. Clinical Review Of The Japanese Experience With Boron Neutron Capture Therapy And A Proposed Strategy Using Epithermal Neutron Beams. J Neurooncol 2003; 62(1-2): 87-99.
34. Kageji T, Nakagawa Y, Kitamura K, et al. Harmacokinetics And Boron Uptake Of BSH (Na 2B12H11SH) In Patientswith Intracranial Tumors. J Neurooncol 1997; 33(1-2): 117-30.
35. Asbury AK, Ojemann RG, Nielson SL, et al. Neuropathologic Study Of Fourteen Cases Of Malignant Brain Tumor Treated By Boron-10 Slow Neutron Capture Therapy. J Neuropath Exp Neur 1972; 31(2): 278-303.
36. Slatkin DN. A History Of Boron Neutron Capture Therapy Of Brain Tumours. Postulation Of A Brain Radiation Dose Tolerance Limit. Brain 1991; 114(4): 1609-29.
37. Goodwin JT, Farr LE, Sweet WH, et al. Pathological Study Of Eight Patients With Glioblastoma Multiforme Treated By Neutron Capture Therapy Using Boron 10. Cancer 1955; 8(3): 601-15.
38. Mishima Y, Ichihashi M, Hatta S, et al. New Thermal Neutron Capture Therapy For Malignant Melanoma. Melanogenesis-Seeking 10B Molecular-Melanoma Cell Interaction From In Vitro To First Clinical Trial. Pigment Cell Res 1989; 2(4): 226-34.
39. Hiratsuka J, Kono M, Mishima Y. RBEs of Thermal Neutron Capture Therapy and 10B(n, a) 7 Li Reaction On Melanoma-Bearing Hamsters. Pigment Cell Res 1989; 2(4): 352-5.
40. Coderre JA, Glass JD, Fairchild RG, et al. Selective Delivery Of Boron By The Melanin Precursor Analog P Boronophenylalanine To Tumorsother Than Melanoma. Cancer Res 1990; 50(1): 388-41.
41. MishimaY, Honda C, Ichihashi M, et al. Treatment Of Malignant Melanoma By Single Neutron Capture Therapy With Melanoma-Seeking 10B Compound. Lancet 1989; 2(8659): 388-9.
42. Yoshino K, Suzuki A, Mori Y, et al. Improvement Of Solubility Of P-Boronophenylalanine By Complex Formation With Monosaccharides. Strahlenther Onkol 1989; 165(2-3): 127-9.
43. Busse PM, Zamenhof RG, Harling OK, et al. The Harvard-MIT BNCT Program. In: Hawthorne MF, Shelly K, Wiersema RJ, editors. Frontiers in Neutron Capture Therapy. Boston, MA: Springer, 2001, 93-123.
44. Kankaanranta L, Seppälä T, Koivunoro H, et al. Boron Neutron Capture Therapy In The Treatment Of Locally Recurred Head-And-Neck Cancer: Final Analysis Of A Phase I / II Trial. Int J Radiat Oncol Biol Phys 2012; 82(1): e67-75.
45. Nakagawa Y, Kageji T, Mizobuchi Y, et al. Clinical Results Of BNCT For Malignant Brain Tumors In Children. Appl Radiat Isot 2009; 67(7-8): S27-30.
46. Uchiyama Y, Matsumoto K, Murakami S, et al. MRI In a Case Of Osteosarcoma In The Temporomandibular Joint. Dentomaxillofac Rad 2014; 43(2): 20130280.
47. Futamura G, Kawabata S, Siba H, et al. A Case Of Radiation-Induced Osteosarcoma Treated Effectively By Boron Neutron Capture Therapy. Radiat Oncol 2014; 9: 237.
48. Malouff TD, Seneviratne DS, Ebner DK, et al. Boron Neutron Capture Therapy: A Review of Clinical Applications. Front Oncol 2021; 11: 601820.
49. Kato I, Ono K, Sakurai Y, et al. Effectiveness of BNCT For Recurrent Head And Neck Malignancies. Appl Radiat Isot 2004; 61(5): 1069-73.
50. Hampel G, Wortmann W, Blaickner M, et al. Irradiation Facility At The TRIGA Mainz For Treatment Of Liver Metastases. Appl Radiat Isot 2009; 67(7-8 Suppl): S238-41.
51. Ringe B, Pichlmayr R, Wittekind C, et al. Surgical Treatment Of Hepatocellular Carcinoma: Experience With Liver Resection And Transplantation In198 Patients. World J Surg 1991; 15(2): 270-85.
52. Zonta A, Prati U, Roveda R, et al. Clinical Lessons From The First Applications Of BNCT On Unresectable Liver Metastases. J Phys Conf Ser 2006; 41: 054.
53. Suzuki M, Nagata K, Masunaga S, et al. Biodistribution Of 10B In A Rat Liver Tumor Model Following Intraarterial Administration Of Sodium Borocaptate (BSH)/ Degradable Starch Microspheres (DSM) Emulsion. Appl Radiat Isot 2004; 61(5): 933-7.
54. Koivunoro H, Bleuel DL, Nastasi U, et al. BNCT Dose Distribution In Liver With Epithermal D-D And D-T Fusion-Based Neutron Beams. Appl Radiat Isot 2004; 61(5): 853-9.
55. Nigg DW. Computational Dosimetry And Treatment Planning Considerations For Neutron Capture Therapy. J Neurooncol 2003; 62(1-2): 75-86.
56. Fukuda H, Hiratsuka J, Honda C, et al. Boron Neutron Capture Therapy Of Malignant Melanoma Using 10B-Paraboronophenylalanine With Special Reference To Evaluation Of Radiation Dose And Damage To The Normal Skin. Radiat Res 1994; 138(3): 435-42.
57. Coderre JA, Elowitz EH, Chadha M, et al. Boron Neutron Capture Therapy For Glioblastoma Multiforme Using p-Boronophenylalanine And Epithermal Neutrons: Trial Design And Early Clinical Results. J Neurooncol 1997; 33: 141-52.
Send email to the article author

Add your comments about this article
Your username or Email:


XML   Persian Abstract   Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Omrani M, Jafari E, Alipour Z, Zarei H. An Introduction to Boron Neutron Therapy (BNCT): Current Status and Future Outlook. Iran South Med J. 2021; 24 (6) :610-625
URL: http://ismj.bpums.ac.ir/article-1-1527-en.html

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 24, Issue 6 (Iranian South Medical Journal 2021) Back to browse issues page
دانشگاه علوم پزشکی بوشهر، طب جنوب ISMJ

Iranian South Medical Journal is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License which allows users to read,
copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly

Copyright © 2022, Iranian South Medical Journal| All Rights Reserved

Persian site map - English site map - Created in 0.05 seconds with 30 queries by YEKTAWEB 4419